Sold as Diupres-250, Diupres-500. Every FDA application for this active ingredient: 1 branded and 6 generic.
As of Nov 14, 2026, FDA lists 7 applications for Chlorothiazide; Reserpine (sold as Diupres-250, Diupres-500), first approved Dec 11, 1958, with 0 new uses approved and 0 published complete response letters.
| Dec 11, 1958 | Diupres-250, Diupres-500NDA 11635 · New combination | Merck | 8 | Discontinued |
| May 6, 1982 | Chlorothiazide-ReserpineANDA 87744 | Pharmobedient | 9 | Discontinued |
| May 6, 1982 | Chlorothiazide-ReserpineANDA 87745 | Pharmobedient | 9 | Discontinued |
| Dec 22, 1983 | Chlorothiazide And ReserpineANDA 88365 | Hikma | 1 | Discontinued |
| Dec 22, 1983 | Chlorothiazide And ReserpineANDA 88557 | Hikma | 3 | Discontinued |
| — | Chlorothiazide W/ ReserpineANDA 84853 | Watson Labs | 2 | Discontinued |
| — | Chlorothiazide W/ ReserpineANDA 88151 | Watson Labs | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Hikma